| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by date.
Page 6: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1501 | 0 | 0 | 1479 1999 MAR 21 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
| 1502 | 4 | 10 | 1528 1999 APR [15] CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
| 1503 | 6 | 11 | 1529 1999 APR [15] CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
| 1504 | 0 | 0 | 1539 1999 APR [15] GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
| 1505 | 0 | 0 | 1540 1999 APR [15] GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
| 1506 | 0 | 0 | 1541 1999 APR [15] GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| 1507 | 0 | 0 | 1542 1999 APR [15] GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
| 1508 | 0 | 0 | 1587 1999 APR [15] NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
| 1509 | 0 | 0 | 1593 1999 APR [15] PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
| 1510 | 11 | 13 | 1594 1999 APR [15] PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1511 | 1 | 1 | 1575 1999 MAY 1 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
| 1512 | 22 | 42 | 1522 1999 MAY [15] BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 10 | 25 |
| 1513 | 24 | 35 | 1523 1999 MAY [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
| 1514 | 4 | 5 | 1527 1999 MAY-JUN [MAY 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
| 1515 | 9 | 27 | 1530 1999 MAY [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
| 1516 | 7 | 11 | 1584 1999 MAY [15] NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 29 | 31 |
| 1517 | 13 | 25 | 1585 1999 MAY [15] NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 110 |
| 1518 | 0 | 0 | 1590 1999 MAY [15] ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
| 1519 | 20 | 40 | 1603 1999 MAY [15] SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
| 1520 | 16 | 32 | 1548 1999 JUN 1 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1521 | 3 | 10 | 1578 1999 19990607-19:57:01 [JUN 07] LUPUS 8(3):248-249 Rua-Figueroa I; Erausquin C; Naranjo A; Carretero-Hernandez G; Rodriguez-Lozano C; De la Rosa P Pustuloderma during cutaneous lupus treatment with thalidomide | 3 | 5 |
| 1522 | 55 | 79 | 1497 1999 JUN [15] BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
| 1523 | 0 | 1 | 1531 1999 JUN [15] CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 1524 | 5 | 17 | 1550 1999 JUN [15] IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
| 1525 | 10 | 28 | 1567 1999 JUN [15] JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 36 |
| 1526 | 10 | 22 | 1595 1999 JUN [15] PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
| 1527 | 10 | 48 | 1563 1999 JUL 1 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 77 | 122 |
| 1528 | 6 | 12 | 1486 1999 JUL [15] ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 14 | 30 |
| 1529 | 11 | 51 | 1524 1999 JUL [15] CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 5 |
| 1530 | 6 | 17 | 1564 1999 JUL [15] JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1531 | 6 | 15 | 1565 1999 JUL [15] JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
| 1532 | 5 | 14 | 1579 1999 JUL [15] MEDICAL HYPOTHESES 53(1):76-77 Sastry PSRK Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis | 5 | 7 |
| 1533 | 14 | 17 | 1599 1999 JUL [15] REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 8 |
| 1534 | 4 | 11 | 1582 1999 JUL 29 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
| 1535 | 2 | 12 | 1583 1999 JUL 29 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
| 1536 | 25 | 30 | 1481 1999 AUG 10 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
| 1537 | 13 | 34 | 1537 1999 AUG [15] ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
| 1538 | 1 | 3 | 1586 1999 AUG [15] NATURE MEDICINE 5(8):853-853 Guenzler V Mechanisms of thalidomide teratogenicity | 2 | 3 |
| 1539 | 5 | 8 | 1596 1999 AUG [15] PHARMACOLOGY & TOXICOLOGY 85(2):103-104 Huang PHT; McBride WG; Tuman WG Interaction of thalidomide with DNA of rabbit embryos: A possible explanation for its immunosuppressant and teratogenic effects | 3 | 3 |
| 1540 | 0 | 0 | 1480 1999 AUG 22 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1541 | 12 | 39 | 1482 1999 SEP 1 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
| 1542 | 1 | 1 | 1483 1999 SEP 1 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 56(17):1721-1725 Keravich DP; Daniels CE Challenges of thalidomide distribution in a hospital setting | 0 | 0 |
| 1543 | 0 | 0 | 1576 1999 SEP 11 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
| 1544 | 11 | 23 | 1488 1999 SEP [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
| 1545 | 44 | 53 | 1489 1999 SEP [15] ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 19 | 28 |
| 1546 | 0 | 0 | 1491 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| 1547 | 0 | 0 | 1492 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
| 1548 | 0 | 0 | 1493 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| 1549 | 0 | 0 | 1494 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
| 1550 | 15 | 23 | 1535 1999 SEP [15] DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1551 | 5 | 12 | 1547 1999 SEP [15] GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
| 1552 | 18 | 29 | 1554 1999 SEP-OCT [SEP 15] INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 6 | 6 |
| 1553 | 0 | 0 | 1495 1999 OCT [15] ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 7 | 8 |
| 1554 | 0 | 0 | 1496 1999 OCT [15] ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 1555 | 20 | 36 | 1538 1999 OCT [15] ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
| 1556 | 14 | 27 | 1557 1999 OCT [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
| 1557 | 7 | 32 | 1568 1999 OCT [15] JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 1558 | 11 | 22 | 1597 1999 OCT [15] PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
| 1559 | 2 | 5 | 1534 1999 19991105-19:22:37 [NOV 05] DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
| 1560 | 9 | 9 | 1561 1999 NOV 12 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1561 | 0 | 0 | 1577 1999 NOV 13 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
| 1562 | 0 | 0 | 1499 1999 NOV 15 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
| 1563 | 0 | 0 | 1500 1999 NOV 15 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 1564 | 0 | 0 | 1501 1999 NOV 15 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
| 1565 | 0 | 0 | 1502 1999 NOV 15 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| 1566 | 0 | 0 | 1503 1999 NOV 15 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
| 1567 | 0 | 0 | 1504 1999 NOV 15 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 1568 | 0 | 0 | 1505 1999 NOV 15 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 1569 | 0 | 0 | 1506 1999 NOV 15 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| 1570 | 0 | 0 | 1507 1999 NOV 15 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1571 | 0 | 0 | 1508 1999 NOV 15 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 1572 | 0 | 0 | 1509 1999 NOV 15 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
| 1573 | 0 | 0 | 1510 1999 NOV 15 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
| 1574 | 0 | 0 | 1511 1999 NOV 15 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 1575 | 0 | 0 | 1512 1999 NOV 15 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 1576 | 0 | 0 | 1513 1999 NOV 15 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
| 1577 | 0 | 0 | 1514 1999 NOV 15 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| 1578 | 0 | 0 | 1515 1999 NOV 15 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 1579 | 0 | 0 | 1516 1999 NOV 15 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
| 1580 | 0 | 0 | 1517 1999 NOV 15 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1581 | 0 | 0 | 1518 1999 NOV 15 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
| 1582 | 0 | 0 | 1519 1999 NOV 15 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
| 1583 | 0 | 0 | 1520 1999 NOV 15 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 1584 | 10 | 31 | 1526 1999 NOV [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 1585 | 12 | 15 | 1562 1999 NOV [15] JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
| 1586 | 27 | 52 | 1566 1999 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 14 |
| 1587 | 11 | 15 | 1571 1999 NOV [15] JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 17 |
| 1588 | 0 | 0 | 1580 1999 NOV [15] MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 1589 | 14 | 40 | 1598 1999 NOV-DEC [NOV 15] REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 10 |
| 1590 | 15 | 35 | 1600 1999 NOV-DEC [NOV 15] SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1591 | 11 | 30 | 1601 1999 NOV-DEC [NOV 15] SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
| 1592 | 84 | 136 | 1604 1999 NOV [15] TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 5 | 16 |
| 1593 | 10 | 37 | 1588 1999 NOV 18 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 284 | 548 |
| 1594 | 8 | 17 | 1589 1999 NOV 18 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
| 1595 | 19 | 39 | 1591 1999 NOV 18 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 13 |
| 1596 | 30 | 79 | 1487 1999 DEC [15] ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
| 1597 | 3 | 44 | 1533 1999 DEC [15] CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
| 1598 | 12 | 70 | 1536 1999 DEC [15] DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
| 1599 | 21 | 33 | 1543 1999 DEC [15] GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 131 |
| 1600 | 19 | 40 | 1544 1999 DEC [15] GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1601 | 23 | 32 | 1545 1999 DEC [15] GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
| 1602 | 9 | 33 | 1546 1999 DEC [15] GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
| 1603 | 43 | 52 | 1549 1999 DEC [15] IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 36 | 45 |
| 1604 | 2 | 29 | 1551 1999 DEC [15] INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
| 1605 | 9 | 16 | 1756 2000 20000106-22:49:05 [JAN 06] LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
| 1606 | 10 | 37 | 1791 2000 20000112-22:12:29 [JAN 12] TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(1):35-47 Fort DJ; Stover EL; Bantle JA; Finch RA Evaluation of the developmental toxicity of thalidomide using Frog Embryo Teratogenesis Assay-Xenopus (FETAX): Biotransformation and detoxification | 6 | 8 |
| 1607 | 4 | 9 | 1607 2000 JAN-FEB [JAN 15] ACTA DERMATO-VENEREOLOGICA 80(1):24-25 Daly BM; Shuster S Antipruritic action of thalidomide | 3 | 9 |
| 1608 | 9 | 24 | 1615 2000 JAN [15] AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 1609 | 3 | 5 | 1625 2000 JAN [15] ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
| 1610 | 6 | 20 | 1626 2000 JAN [15] ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1611 | 15 | 33 | 1631 2000 JAN [15] BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
| 1612 | 0 | 0 | 1687 2000 JAN-FEB [JAN 15] CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 1613 | 8 | 33 | 1693 2000 JAN [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
| 1614 | 53 | 221 | 1700 2000 JAN-FEB [JAN 15] CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
| 1615 | 1 | 2 | 1780 2000 JAN [15] PALLIATIVE MEDICINE 14(1):77-78 Calder K; Bruera E Thalidomide for night sweats in patients with advanced cancer | 6 | 7 |
| 1616 | 9 | 27 | 1784 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
| 1617 | 61 | 96 | 1785 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
| 1618 | 3 | 15 | 1786 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):15-21 Munshi NC; Desikan KR; Barlogie B Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies | 5 | 6 |
| 1619 | 0 | 10 | 1787 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 22 | 26 |
| 1620 | 8 | 35 | 1788 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1621 | 5 | 42 | 1789 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
| 1622 | 1 | 1 | 1766 2000 FEB 3 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
| 1623 | 10 | 20 | 1616 2000 FEB [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
| 1624 | 13 | 38 | 1681 2000 FEB [15] BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 76 | 127 |
| 1625 | 1 | 7 | 1683 2000 FEB [15] BRITISH JOURNAL OF HAEMATOLOGY 108(2):391-393 Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug | 53 | 75 |
| 1626 | 0 | 0 | 1699 2000 FEB [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 1627 | 13 | 20 | 1724 2000 FEB [15] IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
| 1628 | 44 | 51 | 1733 2000 FEB [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
| 1629 | 6 | 34 | 1739 2000 FEB [15] JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 75 | 147 |
| 1630 | 12 | 41 | 1749 2000 FEB [15] JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1631 | 0 | 0 | 1752 2000 FEB [15] JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 1632 | 0 | 68 | 1790 2000 FEB [15] SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| 1633 | 20 | 25 | 1735 2000 20000303-23:21:03 [MAR 03] JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 21 | 21 |
| 1634 | 10 | 34 | 1711 2000 MAR 10 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 16 |
| 1635 | 6 | 16 | 1689 2000 MAR-APR [MAR 15] CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 1636 | 16 | 22 | 1727 2000 MAR [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |
| 1637 | 0 | 0 | 1729 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
| 1638 | 0 | 0 | 1730 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
| 1639 | 0 | 0 | 1731 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
| 1640 | 0 | 0 | 1732 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1641 | 12 | 44 | 1743 2000 MAR [15] JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
| 1642 | 0 | 0 | 1770 2000 MAR [15] ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
| 1643 | 11 | 41 | 1793 2000 MAR [15] TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
| 1644 | 0 | 0 | 1605 2000 MAR 26 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
| 1645 | 1 | 1 | 1767 2000 MAR 30 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-975 Kishi Y; Oki Y; Machida U Thalidomide in multiple myeloma | 3 | 5 |
| 1646 | 1 | 4 | 1768 2000 MAR 30 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-976 Barlogie B Thalidomide in multiple myeloma - Reply | 0 | 0 |
| 1647 | 4 | 18 | 1795 2000 APR 1 TETRAHEDRON LETTERS 41(14):2275-2278 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-gamma-hydroxyglutamic acid | 3 | 7 |
| 1648 | 0 | 0 | 1765 2000 APR 11 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
| 1649 | 71 | 96 | 1613 2000 APR 15 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 58 | 99 |
| 1650 | 83 | 113 | 1630 2000 APR [15] BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1651 | 8 | 19 | 1684 2000 APR [15] BRITISH JOURNAL OF HAEMATOLOGY 109(1):89-96 Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | 88 | 117 |
| 1652 | 0 | 0 | 1706 2000 APR [15] DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
| 1653 | 0 | 0 | 1715 2000 APR [15] GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
| 1654 | 0 | 0 | 1716 2000 APR [15] GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
| 1655 | 0 | 0 | 1717 2000 APR [15] GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
| 1656 | 1 | 1 | 1744 2000 APR [15] JOURNAL OF INFECTIOUS DISEASES 181(4):1521-1521 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (vol 181, pg 954, 2000) | 0 | 0 |
| 1657 | 0 | 0 | 1771 2000 APR [15] ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
| 1658 | 0 | 0 | 1782 2000 APR [15] PEDIATRIC RESEARCH 47(4):264A-264A Hanekom W; Ganiso B; Appolis P; Hughes J; Allin R; Goddard E; Haslett P; Hussey G; Kaplan G Safety and immune effects of thalidomide in HIV-infected children | 0 | 0 |
| 1659 | 14 | 41 | 1738 2000 APR 21 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 31 |
| 1660 | 0 | 0 | 1702 2000 APR 28 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1661 | 0 | 0 | 1714 2000 MAY 11 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 1662 | 11 | 60 | 1614 2000 MAY [15] AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 2 | 23 |
| 1663 | 12 | 33 | 1697 2000 MAY [15] CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
| 1664 | 0 | 0 | 1704 2000 MAY [15] DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
| 1665 | 2 | 2 | 1726 2000 MAY [15] INFLAMMATORY BOWEL DISEASES 6(2):152-153 Katz JA Thalidomide for Crohn's disease: High dose, low dose, or "no doze" at all? Comment | 1 | 1 |
| 1666 | 18 | 27 | 1728 2000 MAY [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
| 1667 | 9 | 15 | 1745 2000 MAY [15] JOURNAL OF INFECTIOUS DISEASES 181(5):1813-1816 Juffermans NP; Verbon A; Olszyna DP; van Deventer SJH; Speelman P; van der Poll T Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4(+) T cells in humans | 3 | 5 |
| 1668 | 102 | 148 | 1764 2000 MAY-JUN [MAY 15] NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
| 1669 | 16 | 59 | 1783 2000 MAY [15] QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
| 1670 | 3 | 14 | 1610 2000 JUN [15] AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 25 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1671 | 91 | 116 | 1617 2000 JUN-JUL [JUN 15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 8 |
| 1672 | 36 | 174 | 1629 2000 JUN 15 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
| 1673 | 2 | 6 | 1679 2000 JUN [15] BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
| 1674 | 20 | 27 | 1751 2000 JUN [15] JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
| 1675 | 19 | 37 | 1797 2000 JUN 15 TOXICOLOGY AND APPLIED PHARMACOLOGY 165(3):237-244 Karrow NA; McCay JA; Brown RD; Musgrove DL; Pettit DA; Munson AE; Germolec DR; White KL Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice | 5 | 8 |
| 1676 | 3 | 13 | 1757 2000 JUN 16 LIFE SCIENCES 67(4):457-461 Thiele A; Thormann M; Hofmann HJ; Naumann WW; Eger K; Hauschildt S A possible role of N-cadherin in thalidomide teratogenicity | 4 | 6 |
| 1677 | 0 | 0 | 1682 2000 JUL [15] BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 1678 | 0 | 0 | 1698 2000 JUL [15] CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
| 1679 | 0 | 0 | 1712 2000 JUL [15] EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
| 1680 | 0 | 0 | 1713 2000 JUL [15] EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1681 | 2 | 2 | 1720 2000 JUL [15] GUT 47(1):156-156 Ryan J Thalidomide treatment of oesophageal ulceration | 0 | 0 |
| 1682 | 13 | 67 | 1740 2000 JUL [15] JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 44 | 82 |
| 1683 | 27 | 40 | 1741 2000 JUL [15] JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 38 | 53 |
| 1684 | 28 | 36 | 1750 2000 JUL [15] JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
| 1685 | 0 | 0 | 1772 2000 JUL [15] ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
| 1686 | 2 | 5 | 1753 2000 AUG 12 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 20 | 27 |
| 1687 | 24 | 45 | 1688 2000 AUG [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 20 |
| 1688 | 7 | 23 | 1705 2000 AUG [15] DIABETES CARE 23(8):1172-1176 Iqbal N; Zayed M; Boden G Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes | 3 | 3 |
| 1689 | 54 | 120 | 1707 2000 AUG [15] DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
| 1690 | 0 | 0 | 1710 2000 AUG-SEP [AUG 15] EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1691 | 4 | 8 | 1718 2000 AUG [15] GASTROENTEROLOGY 119(2):596-596 Fishman SJ; Feins NR; D'Amato RJ; Folkman J Thalidomide therapy for Crohn's disease | 5 | 12 |
| 1692 | 0 | 0 | 1719 2000 AUG-SEP [AUG 15] GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| 1693 | 3 | 20 | 1725 2000 AUG [15] INFLAMMATION 24(4):347-356 Lindsay L; Oliver SJ; Freeman SL; Josien R; Krauss A; Kaplan G Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone | 1 | 5 |
| 1694 | 4 | 17 | 1736 2000 AUG [15] JOURNAL OF CHILD NEUROLOGY 15(8):497-503 Schoeman JF; Springer P; Ravenscroft A; Donald PR; Bekker LG; van Rensburg AJ; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role | 8 | 10 |
| 1695 | 8 | 8 | 1746 2000 AUG [15] JOURNAL OF INFECTIOUS DISEASES 182(2):639-639 Gori A; Rossi MC; Trabattoni D; Marchetti G; Fusi ML; Molteni C; Clerici M; Franzetti F Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection | 6 | 7 |
| 1696 | 4 | 5 | 1747 2000 AUG [15] JOURNAL OF INFECTIOUS DISEASES 182(2):640-640 Kaplan G Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection - Reply | 0 | 0 |
| 1697 | 7 | 16 | 1758 2000 AUG [15] MAYO CLINIC PROCEEDINGS 75(8):842-844 Federman GL; Federman DG Recalcitrant pyoderma gangrenosum treated with thalidomide | 5 | 12 |
| 1698 | 4 | 5 | 1763 2000 AUG [15] MUSCLE & NERVE 23(8):1301-1302 Rao DG; Kane NM; Oware A Thalidomide neuropathy: Role of F-wave monitoring | 5 | 5 |
| 1699 | 5 | 5 | 1608 2000 AUG 18 AIDS 14(12):1859-1861 Gori A; Rossi MC; Marchetti G; Trabattoni D; Molteni C; Cogliati M; Bandera A; Clerici M; Franzetti F Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease | 5 | 7 |
| 1700 | 0 | 0 | 1606 2000 AUG 20 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1701 | 0 | 0 | 1691 2000 AUG 21 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
| 1702 | 17 | 19 | 1734 2000 20000821-22:44:17 [AUG 21] JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
| 1703 | 7 | 12 | 1611 2000 SEP 1 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 57(17):1607-1610 Eriksson T; Wallin R; Hoglund P; Roth B; Qi ZQ; Ostraat O; Bjorkman S Low bioavailability of rectally administered thalidomide | 2 | 2 |
| 1704 | 8 | 25 | 1796 2000 SEP 9 TETRAHEDRON LETTERS 41(37):7151-7155 Luzzio FA; Thomas EM; Figg WD Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine | 4 | 6 |
| 1705 | 17 | 32 | 1609 2000 SEP [15] AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 27 |
| 1706 | 17 | 32 | 1623 2000 SEP [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 16 | 17 |
| 1707 | 0 | 0 | 1627 2000 SEP [15] ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
| 1708 | 0 | 0 | 1628 2000 SEP [15] ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
| 1709 | 4 | 4 | 1685 2000 SEP [15] BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
| 1710 | 13 | 49 | 1694 2000 SEP [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1711 | 17 | 32 | 1708 2000 SEP [15] ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 16 |
| 1712 | 8 | 15 | 1748 2000 SEP [15] JOURNAL OF INFECTIOUS DISEASES 182(3):983-987 Lokensgard JR; Hu SX; van Fenema EM; Sheng WS; Peterson PK Effect of thalidomide on chemokine production by human microglia | 8 | 11 |
| 1713 | 10 | 28 | 1759 2000 SEP [15] MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
| 1714 | 2 | 4 | 1781 2000 SEP [15] PALLIATIVE MEDICINE 14(5):429-431 Deaner PB The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report | 0 | 1 |
| 1715 | 1 | 3 | 1794 2000 SEP [15] TERATOLOGY 62(3):172-173 Adams J; Buttar HS; Chambers C; Collins TFX; Graham JM; Jones KL; Kweder S; Mitala J; Polifka JE; Schwetz BA; Public Affairs Comm Teratology society public affairs committee position paper: Thalidomide | 0 | 1 |
| 1716 | 4 | 6 | 1769 2000 SEP 28 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
| 1717 | 1 | 5 | 1742 2000 OCT 1 JOURNAL OF CLINICAL ONCOLOGY 18(19):3453-3453 Cohen MH Thalidomide in the treatment of high-grade gliomas | 1 | 3 |
| 1718 | 16 | 22 | 1792 2000 20001011-21:35:04 [OCT 11] TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
| 1719 | 0 | 0 | 1612 2000 OCT [15] AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
| 1720 | 9 | 19 | 1680 2000 OCT [15] BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1721 | 22 | 98 | 1690 2000 OCT [15] CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
| 1722 | 5 | 15 | 1692 2000 OCT [15] CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
| 1723 | 4 | 9 | 1721 2000 OCT [15] HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
| 1724 | 0 | 0 | 1722 2000 OCT [15] HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| 1725 | 10 | 31 | 1632 2000 NOV 1 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 89 | 172 |
| 1726 | 0 | 0 | 1618 2000 20001109-19:09:28 [NOV 09] ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
| 1727 | 0 | 0 | 1619 2000 20001109-19:09:28 [NOV 09] ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
| 1728 | 0 | 0 | 1620 2000 20001115-18:58:21 [NOV 15] ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
| 1729 | 0 | 0 | 1621 2000 20001115-18:58:21 [NOV 15] ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
| 1730 | 23 | 38 | 1622 2000 NOV [15] ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1731 | 0 | 0 | 1695 2000 NOV [15] CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
| 1732 | 13 | 49 | 1696 2000 NOV [15] CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
| 1733 | 49 | 95 | 1701 2000 NOV [15] CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 40 |
| 1734 | 0 | 0 | 1703 2000 NOV [15] DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
| 1735 | 22 | 40 | 1723 2000 NOV [15] HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
| 1736 | 0 | 0 | 1633 2000 NOV 16 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
| 1737 | 0 | 0 | 1634 2000 NOV 16 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
| 1738 | 0 | 0 | 1635 2000 NOV 16 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
| 1739 | 0 | 0 | 1636 2000 NOV 16 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
| 1740 | 0 | 0 | 1637 2000 NOV 16 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1741 | 0 | 0 | 1638 2000 NOV 16 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
| 1742 | 0 | 0 | 1639 2000 NOV 16 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
| 1743 | 0 | 0 | 1640 2000 NOV 16 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
| 1744 | 0 | 0 | 1641 2000 NOV 16 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
| 1745 | 0 | 0 | 1642 2000 NOV 16 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
| 1746 | 0 | 0 | 1643 2000 NOV 16 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
| 1747 | 0 | 0 | 1644 2000 NOV 16 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 1748 | 0 | 0 | 1645 2000 NOV 16 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
| 1749 | 0 | 0 | 1646 2000 NOV 16 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
| 1750 | 0 | 0 | 1647 2000 NOV 16 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1751 | 0 | 0 | 1648 2000 NOV 16 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
| 1752 | 0 | 0 | 1649 2000 NOV 16 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
| 1753 | 0 | 0 | 1650 2000 NOV 16 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
| 1754 | 0 | 0 | 1651 2000 NOV 16 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
| 1755 | 0 | 0 | 1652 2000 NOV 16 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
| 1756 | 0 | 0 | 1653 2000 NOV 16 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
| 1757 | 0 | 0 | 1654 2000 NOV 16 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
| 1758 | 0 | 0 | 1655 2000 NOV 16 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
| 1759 | 0 | 0 | 1656 2000 NOV 16 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
| 1760 | 0 | 0 | 1657 2000 NOV 16 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1761 | 0 | 0 | 1658 2000 NOV 16 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
| 1762 | 0 | 0 | 1659 2000 NOV 16 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
| 1763 | 0 | 0 | 1660 2000 NOV 16 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
| 1764 | 0 | 0 | 1661 2000 NOV 16 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
| 1765 | 0 | 0 | 1662 2000 NOV 16 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
| 1766 | 0 | 0 | 1663 2000 NOV 16 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
| 1767 | 0 | 0 | 1664 2000 NOV 16 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
| 1768 | 0 | 0 | 1665 2000 NOV 16 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
| 1769 | 0 | 0 | 1666 2000 NOV 16 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
| 1770 | 0 | 0 | 1667 2000 NOV 16 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1771 | 0 | 0 | 1668 2000 NOV 16 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
| 1772 | 0 | 0 | 1669 2000 NOV 16 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
| 1773 | 0 | 0 | 1670 2000 NOV 16 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
| 1774 | 0 | 0 | 1671 2000 NOV 16 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
| 1775 | 0 | 0 | 1672 2000 NOV 16 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| 1776 | 0 | 0 | 1673 2000 NOV 16 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
| 1777 | 0 | 0 | 1674 2000 NOV 16 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
| 1778 | 0 | 0 | 1675 2000 NOV 16 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
| 1779 | 0 | 0 | 1676 2000 NOV 16 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
| 1780 | 4 | 10 | 1760 2000 20001127-20:19:24 [NOV 27] MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1781 | 4 | 8 | 1677 2000 DEC 1 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
| 1782 | 1 | 3 | 1678 2000 DEC 1 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 23 |
| 1783 | 8 | 38 | 1779 2000 DEC 1 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 20 |
| 1784 | 4 | 4 | 1624 2000 DEC [15] ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
| 1785 | 1 | 1 | 1686 2000 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 111(3):986-986 Myers B; Crouch D; Dolan G Thalidomide treatment in advanced refractory myeloma | 5 | 5 |
| 1786 | 7 | 20 | 1709 2000 DEC [15] EUROPEAN CYTOKINE NETWORK 11(4):574-579 van Crevel R; Vonk AG; Netea MG; Kullberg BJ; van der Meer JWM Modulation of LPS-, PHA-and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide | 2 | 3 |
| 1787 | 1 | 1 | 1737 2000 DEC [15] JOURNAL OF CHILD NEUROLOGY 15(12):838-838 Schoeman JF Thalidomide therapy in childhood tuberculous meningitis | 3 | 4 |
| 1788 | 16 | 19 | 1754 2000 DEC [15] LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
| 1789 | 0 | 0 | 1755 2000 DEC [15] LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| 1790 | 0 | 0 | 1761 2000 DEC [15] MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1791 | 0 | 0 | 1762 2000 DEC [15] MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
| 1792 | 0 | 0 | 1773 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
| 1793 | 14 | 57 | 1774 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
| 1794 | 4 | 12 | 1775 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
| 1795 | 7 | 16 | 1776 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):25-28 Hwu WJ New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide | 6 | 14 |
| 1796 | 2 | 8 | 1777 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):29-32 Govindarajan R Irinotecan and thalidomide in metastatic colorectal cancer | 7 | 12 |
| 1797 | 7 | 18 | 1778 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):33-36 Amato R Thalidomide for recurrent renal-cell cancer in a 40-year-old man | 2 | 2 |
| 1798 | 1 | 1 | 1805 2001 JAN [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(1):87-87 Schmutz JL; Barbaud A; Trechot P Buccal lichen after thalidomide | 0 | 0 |
| 1799 | 4 | 4 | 1880 2001 JAN [15] BONE MARROW TRANSPLANTATION 27(2):229-230 Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K Severe cutaneous ulceration following treatment with thalidomide for GVHD | 0 | 1 |
| 1800 | 100 | 115 | 1913 2001 JAN [15] DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
Page 6: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22